[go: up one dir, main page]

SG10201401700XA - A novel formulation of diclofenac - Google Patents

A novel formulation of diclofenac

Info

Publication number
SG10201401700XA
SG10201401700XA SG10201401700XA SG10201401700XA SG10201401700XA SG 10201401700X A SG10201401700X A SG 10201401700XA SG 10201401700X A SG10201401700X A SG 10201401700XA SG 10201401700X A SG10201401700X A SG 10201401700XA SG 10201401700X A SG10201401700X A SG 10201401700XA
Authority
SG
Singapore
Prior art keywords
diclofenac
novel formulation
formulation
novel
Prior art date
Application number
SG10201401700XA
Inventor
Aaron Dodd
Felix Meiser
Marck Norret
Adrian Russell
H William Bosch
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43010610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201401700X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2009901748A external-priority patent/AU2009901748A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of SG10201401700XA publication Critical patent/SG10201401700XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
SG10201401700XA 2009-04-24 2010-04-23 A novel formulation of diclofenac SG10201401700XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17229109P 2009-04-24 2009-04-24
AU2009901748A AU2009901748A0 (en) 2009-04-24 A Novel Formulation of Diclofenac

Publications (1)

Publication Number Publication Date
SG10201401700XA true SG10201401700XA (en) 2014-06-27

Family

ID=43010610

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011077450A SG175314A1 (en) 2009-04-24 2010-04-23 A novel formulation of diclofenac
SG10201401700XA SG10201401700XA (en) 2009-04-24 2010-04-23 A novel formulation of diclofenac

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011077450A SG175314A1 (en) 2009-04-24 2010-04-23 A novel formulation of diclofenac

Country Status (23)

Country Link
US (12) US8735450B2 (en)
EP (2) EP2421525B1 (en)
JP (2) JP6222924B2 (en)
KR (5) KR20120029398A (en)
CN (5) CN106727424A (en)
AP (2) AP3774A (en)
AU (1) AU2010239080B2 (en)
CA (1) CA2759123C (en)
CO (1) CO6470810A2 (en)
DK (1) DK2421525T3 (en)
EA (1) EA201171285A1 (en)
HK (2) HK1202061A1 (en)
IL (1) IL215869B (en)
MA (1) MA33295B1 (en)
MX (2) MX337619B (en)
MY (1) MY168079A (en)
NZ (3) NZ595987A (en)
PH (1) PH12015500301A1 (en)
SG (2) SG175314A1 (en)
TN (1) TN2011000543A1 (en)
UA (1) UA106232C2 (en)
WO (1) WO2010121327A1 (en)
ZA (1) ZA201108650B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5508003B2 (en) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド Process for the preparation of biologically active compounds in nanoparticulate form
AU2010239160B2 (en) * 2009-04-24 2014-10-02 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
CN106727424A (en) 2009-04-24 2017-05-31 伊休蒂卡有限公司 The novel form of Diclofenac
BRPI1014275B8 (en) 2009-04-24 2021-05-25 Iceutica Pty Ltd composition comprising indomethacin particles dispersed in at least two partially ground mill materials
CA2759108C (en) * 2009-04-24 2020-05-05 Iceutica Pty Ltd Solid unit dosage forms containing celecoxib
JP5909796B2 (en) * 2012-03-02 2016-04-27 株式会社サンギ Method for improving water solubility of poorly soluble substances
WO2014060856A1 (en) * 2012-10-16 2014-04-24 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
SG11201507681PA (en) * 2013-03-15 2015-10-29 Iceutica Inc Abiraterone acetate formulation
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US20180153835A1 (en) * 2015-06-05 2018-06-07 Lupin Limited Compositions of diclofenac acid
DK3411031T3 (en) 2016-02-04 2024-10-21 Cindome Pharma Inc Deuterated domperidone preparations and methods for therapy of disorders
CN106267209A (en) * 2016-07-18 2017-01-04 苏州朗易生物医药研究有限公司 Low dosage non-steroidal anti-inflammatory class pharmaceutical composition and preparation technology thereof
EP4549008A1 (en) 2016-11-10 2025-05-07 Medisca Pharmaceutique Inc. Pharmaceutical compounding methods and systems
CN106580886A (en) * 2016-12-05 2017-04-26 北京万全德众医药生物技术有限公司 Diclofenac potassium powder and preparation method thereof
KR102771163B1 (en) * 2017-04-07 2025-02-25 엠에이에이 래보러토리스, 인코포레이티드 Method for improving the solubility and bioavailability of a therapeutic agent
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
KR20240125702A (en) 2017-06-30 2024-08-19 신돔 파마, 인크. Deuterated domperidone compositions, methods, and preparation
WO2019030773A1 (en) * 2017-08-10 2019-02-14 Sarudbhava Formulations Private Limited Low-dose diclofenac compositions
KR20220007198A (en) 2020-07-10 2022-01-18 오훈 The construction method of hole processing device and hole for hole cup replacement of golf course
CN114088624B (en) * 2021-11-09 2022-08-26 北京中检葆泰生物技术有限公司 Equipment for detecting surface regularity of grain particles
CN115317464B (en) * 2022-09-01 2023-08-08 苏州弘森药业股份有限公司 Potassium diclofenac microcapsule and preparation method thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (en) 1989-08-04 1997-08-20 田辺製薬株式会社 Ultrafine particle method for poorly soluble drugs
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
SE9600070D0 (en) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
IT1286778B1 (en) * 1996-11-20 1998-07-17 Alfa Wassermann Spa CAPSULES CONTAINING DICLOFENAC OR ITS SALTS IN SOLUTION
WO1998047499A1 (en) * 1997-04-22 1998-10-29 Nippon Kayaku Kabushiki Kaisha Flutamide preparations and method for manufacturing the same
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
CN100457090C (en) 2000-08-31 2009-02-04 斯凯伊药品加拿大公司 Grinding particles
US6908626B2 (en) 2001-10-12 2005-06-21 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
GB0320522D0 (en) 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
UA89513C2 (en) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Nanoparticulate raloxifene hydrochloride composition
US20060159766A1 (en) 2004-12-15 2006-07-20 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
CA2593862C (en) * 2004-12-31 2014-10-21 Iceutica Pty Ltd Nanoparticle composition and methods for synthesis thereof
WO2006099121A2 (en) 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
SI1877059T1 (en) 2005-04-28 2010-07-30 Wyeth Llc Micronized tanaproget and compostions containing same
JO3352B1 (en) * 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa Diclofenac formulations and methods of use
EP1973523A2 (en) * 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
DE602006009710D1 (en) 2005-12-15 2009-11-19 Acusphere Inc METHOD FOR THE PRODUCTION OF PHARMACEUTICAL FORMULATIONS ON PARTICLE BASIS FOR PARENTERAL ADMINISTRATION
JP5508003B2 (en) * 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド Process for the preparation of biologically active compounds in nanoparticulate form
NZ614995A (en) 2006-06-30 2015-03-27 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
CN106727424A (en) 2009-04-24 2017-05-31 伊休蒂卡有限公司 The novel form of Diclofenac

Also Published As

Publication number Publication date
EP2421525B1 (en) 2017-06-07
US8999387B2 (en) 2015-04-07
JP6222924B2 (en) 2017-11-01
NZ710383A (en) 2017-04-28
BRPI1014272A2 (en) 2016-10-18
MX2011011222A (en) 2012-02-08
US9180096B2 (en) 2015-11-10
EP2421525A4 (en) 2013-01-23
US20140248359A1 (en) 2014-09-04
CN106727424A (en) 2017-05-31
EP3290030A1 (en) 2018-03-07
US20150150805A1 (en) 2015-06-04
US20160067199A1 (en) 2016-03-10
US9017721B2 (en) 2015-04-28
SG175314A1 (en) 2011-11-28
US20170100356A1 (en) 2017-04-13
US20130209569A1 (en) 2013-08-15
KR20170002683A (en) 2017-01-06
KR20140124873A (en) 2014-10-27
CN102438610A (en) 2012-05-02
US8679544B2 (en) 2014-03-25
US20140220121A1 (en) 2014-08-07
CO6470810A2 (en) 2012-06-29
HK1202061A1 (en) 2015-09-18
CN106420667A (en) 2017-02-22
UA106232C2 (en) 2014-08-11
EP2421525A1 (en) 2012-02-29
MY168079A (en) 2018-10-11
MX347290B (en) 2017-04-17
US20120135047A1 (en) 2012-05-31
KR101580656B1 (en) 2015-12-30
JP2012524723A (en) 2012-10-18
KR20150086563A (en) 2015-07-28
ZA201108650B (en) 2013-01-30
US20160058707A1 (en) 2016-03-03
DK2421525T3 (en) 2017-09-25
CA2759123C (en) 2019-01-15
EA201171285A1 (en) 2012-05-30
PH12015500301B1 (en) 2015-12-07
US8735450B2 (en) 2014-05-27
IL215869A0 (en) 2012-01-31
IL215869B (en) 2019-02-28
WO2010121327A1 (en) 2010-10-28
JP6154846B2 (en) 2017-06-28
NZ595987A (en) 2014-02-28
CN106727477A (en) 2017-05-31
CA2759123A1 (en) 2010-10-28
AP2011005989A0 (en) 2011-12-31
US20150157573A1 (en) 2015-06-11
JP2015157851A (en) 2015-09-03
TN2011000543A1 (en) 2013-05-24
MA33295B1 (en) 2012-05-02
HK1231383A1 (en) 2017-12-22
PH12015500301A1 (en) 2015-12-07
MX337619B (en) 2016-03-10
US20150150824A1 (en) 2015-06-04
NZ620887A (en) 2015-08-28
AP2015008933A0 (en) 2015-12-31
AU2010239080A1 (en) 2011-11-10
US20180296514A1 (en) 2018-10-18
KR20150018647A (en) 2015-02-23
AP3774A (en) 2016-08-31
US9173854B2 (en) 2015-11-03
CN104161743A (en) 2014-11-26
AU2010239080B2 (en) 2014-08-28
US9180095B2 (en) 2015-11-10
US20150150823A1 (en) 2015-06-04
US9186328B2 (en) 2015-11-17
KR20120029398A (en) 2012-03-26

Similar Documents

Publication Publication Date Title
AP3774A (en) A novel formulation of diclofenac
ZA201108648B (en) A novel formulation of naproxen
AP3628A (en) A novel formulation of indomethacin
EP2339918A4 (en) Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide
AP3659A (en) A novel formulation of meloxicam
IL215864A0 (en) A novel formulation of metaxalone
PL2258339T3 (en) A tooth-cleaning formulation
IL216256A0 (en) A pharmaceutical composition
ZA201304633B (en) A pharmaceutical composition
ZA201107122B (en) Stable pharmaceutical compositions of diclofenac
GB0813347D0 (en) A set of parts
GB2479073B (en) A set of n separable members
IL257014A (en) A novel formulation of meloxicam
ZA201201003B (en) A pharmaceutical composition
AU2009901748A0 (en) A Novel Formulation of Diclofenac
IL256841B (en) A novel formulation of metaxalone
AU2009901746A0 (en) A Novel Formulation of Naproxen
GB0904499D0 (en) A set of parts
GB2478958B (en) A set of n separable members
AU2009901742A0 (en) A Novel Formulation of Meloxicam
AU2009901743A0 (en) A Novel Formulation of Metaxalone
GB201008388D0 (en) A formulation
GB0919237D0 (en) Improvements of a device